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PURPOSE. This work aimed at describing the time course of vitreous clearance through the use
of positron emission tomography (PET) as a noninvasive tool for pharmacokinetic studies of
intravitreal injection.
METHODS. The pharmacokinetic profile of intravitreal injections of molecules labeled with
18Fluorine (18F) was evaluated in adult Sprague Dawley rats by using a dedicated small-animal
PET/computed tomography scanner. Different conditions were studied: three molecules
radiolabeled with 18F (18F-FDG, 18F-NaF, and 18F-Choline), three volumes of intravitreal
injections (7, 4, and 2 lL), and absence or presence of eye inflammation (uveitis).
RESULTS. Our results showed that there are significant pharmacokinetic differences among the
radiolabeled molecules studied but not among the injected volumes. The presence or absence
of uveitis was an important factor in vitreous clearance, since the elimination of the drug was
clearly increased when this condition is present.
CONCLUSIONS. Intravitreal pharmacokinetic studies based on the use of dedicated PET imaging
can be of potential interest as noninvasive tools in ophthalmic drug development in small
animals.
Keywords: intravitreal injection, radiolabeled molecules, vitreous clearance, intravitreal
pharmacokinetics, PET
To date, most topical and systemic drugs have not achievedadequate therapeutic levels in the vitreous, mainly owing to
the existence of different physiological barriers.1 On one hand,
topically instilled drugs are diluted by the tear film, thus causing
significant drug loss in the lachrymal flow,2 and furthermore
their physicochemical characteristics must be adequate to cross
the cornea.3 On the other hand, the blood–retinal barrier
(BRB), which comprises the retinal pigment epithelium and the
tightly sealed walls of the retinal capillaries, complicates the
arrival of systemic drugs to the vitreous.4 For these reasons,
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intravitreal administration has become an effective way to
deliver drugs to the vitreous cavity, allowing high drug
concentrations.5
To achieve a sustained therapeutic drug concentration in
the vitreous, the frequency of administration should be based
on the half-life of the drug (t1/2). Regarding this question,
several in vitro models have been proposed for the study of
intravitreal pharmacokinetics, which take into account all
aspects of the ocular anatomy and physiology.6–9 However, one
aspect that should be taken into consideration in the in vitro
pharmacokinetic studies is the absence of convection,10–13
even though the principal mechanism of transport through the
vitreous is diffusion, and convection does not play a relevant
role in the kinetics of small molecules. Other issues such as
protein binding, melanin binding, drug metabolism, or active
transport are usually not taken into account in the in vitro
studies.8,14 On the other hand, in vivo classical pharmacoki-
netic studies of intravitreal injections are limited because
invasive techniques are involved.15,16
In recent years, molecular imaging techniques have
become a turning point for the development and pharmaco-
kinetic study of new drugs. These techniques involve
noninvasive procedures in order to significantly decrease
the number of animals used by increasing the number of
measurements on each animal.17,18 In particular for the field
of intravitreal drugs, single photon emission computed
tomography and magnetic resonance image (MRI) have been
the most commonly used imaging techniques, mainly to study
pharmacokinetics14,19 and the release of drugs from implants
and liposomes.20–22
However, in pharmacokinetic studies performed with MRI,
the molecules used for the labeling of the drug usually have
very high molecular weight, which can alter the properties of
the original drug.21
The use of positron emission tomography (PET) has made it
possible to label drugs with small b-emitting radioisotopes.23
Current integrated PET/computed tomography (CT) scanners
allow visualization of radiolabeled molecules by using a direct
and noninvasive methodology, and the follow-up of the same
subject over time to determine the pharmacokinetic properties
of intravitreal injections.24–26
Different radionuclides can be used to elaborate radiotrac-
ers for PET scanning. The most commonly used radionuclides
are typically isotopes with short half-lives such as 11C, 13N, 15O,
18F, 68Ga, 82Rb, or with longer half-lives such as 124I or 89Zr. 18F
is one of the most widely used because it is easily produced
with a cyclotron, its positron energy of emission is 0.64 MeV, it
is safe for patients, and it allows to obtain images with high
resolution. Moreover, its half-life is long enough to be able to
produce commercially manufactured fluorinated radiotracers
at off-site locations and to be shipped to imaging services. In
practice, 18F radionuclide is linked to different molecules to
achieve selective transport and distribution.27
Drug clearance in the vitreous can be influenced by various
factors that include molecular weight, physicochemical prop-
erties of the drug, surgical procedure, injected volumes, and
presence of ocular inflammation.1 Also, the mechanisms of
membrane transport and plasmatic clearance can highly
influence the distribution and elimination of drugs after
intravitreal administration. For this reason, fluorodeoxyglucose
(18F-FDG), 18F-choline (18F-Choline), and 18F–sodium fluoride
(18F-NaF) were selected in our study because of their different
molecular weight, polarity, and transport mechanism across
biological membranes. The aim of the present work was to
study the effect of some of these factors on the vitreous
clearance by using dedicated PET/CT imaging techniques for in
vivo studies in rats.
MATERIALS AND METHODS
Our work was designed as an experimental study in rats
scanned in a dedicated PET/CT system after intravitreal
injections of different radiolabeled molecules, different vol-
umes, and absence/presence of inflammatory eye disease
(uveitis).
Animals
This study was carried out on male adult Sprague Dawley rats
with an average weight of 300 g, supplied by the animal facility
of the University of Santiago de Compostela (Santiago de
Compostela, Spain). During the experiments, the animals were
kept in individual cages with free access to food and water in a
room under controlled temperature (228C 6 18C) and humidity
(60% 6 5%) and with day–night cycles regulated by artificial
light (12/12 hours). The animals were treated as indicated in
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and according to the guidelines for laboratory
animals.28,29 Experiments were approved by the Galician
Network Committee for Ethical Research and followed the
Spanish and European Union (EU) rules (86/609/CEE, 2003/
65/CE, 2010/63/EU, RD 1201/2005, and RD53/2013).
Intravitreal Injection Procedure
Intravitreal injection was performed according to the proce-
dure described previously by Chiu et al.30 Firstly, the animals
were placed in a gas chamber containing 2% isoflurane in
oxygen. When unconscious, the animals were removed from
the chamber but kept under anesthesia with a mask (1.5%
isoflurane in oxygen). The procedure was initiated by applying
one drop of topical anesthesia (Colircusi Anestesico Doble:
tetracaine 1 mg/mL and oxybuprocaine 4 mg/mL) on the eye
followed by mydriatic eye drops (phenylephrine 100 mg/mL
[Colircusi Fenilefrina] and tropicamide 10 mg/mL [Colircusi
Tropicamide]) to visualize the eye fundus. Thereafter, radiola-
beled molecules were injected into the vitreous through the
pars plana by using a Hamilton syringe with a 34-G needle. The
injection procedure was performed with a surgical microscope
(Takagi OM-5 220-2; Takagi, Tokyo, Japan). Pictures of the
procedure were taken by means of a digital camera (Nikon D-
200; Nikon, Tokyo, Japan) attached to the microscope. Eyes
with lens damage, or with significant bleeding when the
intravitreal injection was made, were discarded from the study.
Experiments
The experiments were carried out by using intravitreal
injections with three radiolabeled molecules and three
different injection volumes, in healthy eyes and in eyes with
lipopolysaccharide (LPS)–induced uveitis.
Effect of the Type of Injected Radiolabeled
Molecules
Three different molecules were labeled with 18F to evaluate
the intravitreal pharmacokinetics. The radiolabeled molecules
to be injected were 18F-NaF, 18F-FDG, and 18F-Choline, with
molecular weights of 41, 182, and 122 g/mol, respectively
(Fig. 1).
The radioisotope 18F was obtained from the nuclear
reaction 18O (proton, neutron) carried out in our PET Trace
800 cyclotron, according to the method described by Saha.31
The radiosynthesis of 18F-Na was made with a carbonate-type
anion-exchange resin column, in such a way that the 18F is
retained into the column and it is recovered as 18F–sodium
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fluoride by elution with potassium carbonate solution. 18F-FDG
and 18F-Choline were produced on a TRACERlab MX synthe-
sizer (GE Healthcare, Waukesah, WI, USA) by using cassettes
and reagent kits from ABX (Advanced Biochemical Com-
pounds, Radeberg, Germany). The nucleophilic substitution
standard method was used in the case of 18F-FDG and for the
reaction of 18F-fluoromethyl triflate with dimethylethanol-
amine on a Sep-Pak column used in the case of 18F-Choline.32,33
All procedures to obtain radiolabeled molecules were
performed under good-manufacturing-practice conditions fol-
lowing the specific standards of European Pharmacopoeia.34
The purity and stability quality control requirements were
undertaken via high-pressure liquid chromatography/ion chro-
matography (930 Compact IC Flex con; Metrohm AG, Herisau,
Switzerland) and thin layer chromatography. Osmolality
(mOsm/kg) and pH were determined with a vapor pressure
osmometer (VAPRO 5520; ELITECH Group, Paris, France) and a
pH meter (WTW inoLab; WTW, Weilheim, Germany).
Effect of the Injected Volumes
The effect of the injected volume on the intravitreal
pharmacokinetics of the abovementioned molecules was
evaluated by using three different volumes: 2, 4, and 7 lL.
Effect of the Presence of Inflammation
Intravitreal pharmacokinetics was assessed in a uveitis animal
model previously used by our group33 and then compared to
the intravitreal pharmacokinetics in healthy eyes. To induce
uveitis, rats were inoculated into the right posterior paw with 1
mg/kg Escherichia coli LPS diluted in 0.1 mL phosphate-
buffered saline by using a BD Micro-Fine syringe (BD, Oxford,
UK) with 30-G needles. The presence of uveitis was assessed
by direct inspection of the eye, using the surgical microscope.
The animals were kept under such conditions for 24 hours. To
reduce the number of animals, the influence of volume and
presence or absence of uveitis were examined only for 18F-NaF
(monoexponential kinetics) and 18F-FDG (biexponential kinet-
ics). Four animals (eight eyes) were used in each condition
studied.
Data Acquisition and Analysis
PET Data Acquisition. After the intravitreal injections of 1
MBq in each eye for all experimental conditions, dynamic PET
acquisition was carried out to generate eight images of 15
minutes’ duration for the first 1.5 hours. Afterwards, single PET
images were obtained at 4 and 6 hours after drug administra-
tion. PET and CT images were acquired by using an Albira PET/
CT Preclinical Imaging System (Bruker Biospin, Woodbridge,
CT, USA). Animals were kept under anesthesia with a mask
(1.5% isoflurane in oxygen). Respiration frequency and body
temperature were monitored during the anesthesia period. The
PET subsystem comprises three rings of eight compact
modules based on monolithic crystals coupled to multianode
photomultiplier tubes, forming an octagon with an axial field
of view (FOV) of 40 mm per ring and a transaxial FOV of 80
mm in diameter. The CT system comprises a commercially
available microfocus x-ray tube and a CsI scintillator 2D
pixelated flat panel x-ray detector. Scatter and random
coincidences were corrected by using the protocols imple-
mented in the scanner. Attenuation correction was not
performed. Images were reconstructed by using the maximum
likelihood expectation maximization algorithm. Twelve itera-
tions were performed with a reconstructed image pixel size of
0.4 3 0.4 3 0.4 mm3.
PET Data Analysis. After reconstruction, quantitative
measurements were obtained by using the Amide’s Medical
Image Data Examiner.35 Different regions of interest (ROIs)
were manually drawn containing the signal on each eye. The
ROIs were then replicated on the different temporal image
frames to obtain the decrease curve of the radioisotope over
time, conveniently corrected for radioactive decay.
Statistical Analysis. The curves of percentage of radio-
tracer in the eye versus time were fitted to the mono- and
bicompartimental pharmacokinetic model by using nonlinear
least squares regression analysis. The area under the percent-
age of radiotracer time curve AUC3600 from zero to infinity was
calculated by log-trapezoidal rule. The statistical analysis of
experiments was performed by using a 1-way analysis of
variance (ANOVA) and Tukey’s multiple comparisons test. The
nonlinear fitting and the statistical analysis were made by using
the GraphPad Prism 6.0 software (2014; GraphPad Software,
Inc., San Diego, CA, USA).
RESULTS
All radiolabeled molecules were clearly detected in the vitreous
cavity at the initial time of the study and it was possible to
observe how the signal decreased over time. Figure 2 shows
the coronal views of the fused PET/CT images from the initial
frame (10 minutes after the injection) to the last frame (360
minutes after the injection).
FIGURE 1. Chemical structure of (A) 18F-Choline, (B) 18F-FDG, and (C)
18F-NaF.
FIGURE 2. Fused image PET/CT showing the signal evolution in the rat eyes throughout time (minutes).
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Effect of the Type of Radiolabeled Molecules
The values measured from the ROI, containing each eye
throughout time, were obtained for the three radiolabeled
molecules, giving rise to significantly different kinetic curves
(Fig. 3A). On the one hand, the clearance curves from 18F-FDG
and 18F-Choline tracers appeared to fit a two-compartment
model with a biphasic clearance from the vitreous. The
obtained average intravitreal half-lives for these radiolabeled
molecules were13.99 minutes for 18F-FDG and 35.18 minutes
for 18F-Choline for the initial rapid elimination phase (a), and
214.2 minutes and 1351 minutes, respectively, for the slow
elimination phase (b). Table 1 shows the pharmacokinetic
parameters obtained by fitting the data to a bicompartmental
model. On the other hand, the clearance curve from 18F-Na
showed a one-compartment pharmacokinetic model, and the
average intravitreal half-life was 113.2 minutes. Table 2 shows
the pharmacokinetic parameters obtained by fitting the data to
a one-compartment pharmacokinetic model.
When comparing the area under the curve between 0 and
360 minutes (AUC3600 ) among three radiolabeled molecules, it
was observed that 18F-Choline remains significantly longer in
the eye than 18F-FDG and 18F-NaF (Fig. 3B).
The radiolabeled molecules leave the eye and reach the
systemic circulation, following different kinetic curves. Fur-
thermore, the distribution at system level is also significantly
different. Figure 4 shows that 18F-NaF is captured by bone
structures, while 18F-FDG and 18F-Choline are captured by
internal organs.
The radiolabeled molecules used for the intravitreal
injection had radiochemical purity for 18F-FDG higher than
95% with a specific activity of approximately 1000 MBq/mL.
The 18F-Choline had radiochemical purity higher than 95%
with a specific activity of approximately 500 MBq/mL. All
radiotracers showed percentages of fluorine bound to the
radiotracer that were higher than 95% at 8 hours post
synthesis. The osmolality of all radiolabeled solutions was
approximately 280 6 10 mOsm/kg with a pH »7.4.
Effect of the Injected Volumes
Figure 5 shows no differences between the different volumes
of intravitreal injections (2, 4, and 7 lL) for 18F-Na and 18F-FDG
radioisotopes, which follow the same kinetics as previously
described in Figure 3A. Tables 1 and 2 show that no statistically
significant differences were found between pharmacokinetic
parameters in relation to the injected volumes of both 18F-FDG
(Table 1) and 18F-Na (Table 2). Finally, it should be noted that a
transient vascular collapse in the retinal vessels was observed
after administration of 7 lL, but not for 2 and 4 lL.
Effect of the Presence of Inflammation
Figure 6A shows that inflammation slightly, but with statistical
significance, increased the vitreous clearance of 18F-FDG. This
effect was quantified by comparing the AUC3600 of radiolabeled
molecules in uveitis and under normal conditions. Figure 6B
FIGURE 3. Influence of the drug type on its intravitreal release (mean
6 SD, n¼ 8). (A) Intravitreal pharmacokinetic profile of 18F-FDG, 18F-
NaF, and 18F-Choline after intravitreal injection of 4 lL. (B)
Representation of AUC3600 (% min) for all radiotracers. *1-way ANOVA
analysis and Tukey multiple comparison test show significant
differences among the three different compounds (a < 0.01).





7 lL* 7 lLNormal† Uveitis†
a, min1 0.0336 0.03341 0.0416 0.0495 0.01970
t1/2a, min 20.65 20.75 16.66 13.99 35.18
B, min1 0.00285 0.002421 0.00218 0.00324 0.00051
t1/2b, min 243.0 286.4 317.8 214.2 1351
AUC3600 , % min 70.13 6 5.31 88.15 6 7.86 70.01 6 5.70 82.05 6 15.67 201.3 6 18.83
R2 0.9958 0.9958 0.9938 0.9963 0.9971
* No statistical differences for AUC3600 (% min) were observed between different injection volumes (a not significant [n.s.]).
† Statistical differences for AUC3600 (% min) between normal and uveitis eyes for a < 0.01.
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shows that eyes with uveitis had smaller AUC3600 than normal
eyes. In addition, statistically significant differences were found
between the pharmacokinetic parameters in uveitis and
normal conditions for the case of 18F-FDG (Table 1). It must
be mentioned that animals receiving an LPS injection
developed a fibrinous reaction in the anterior chamber of the
eye, which produced a pupillary membrane and an irregular
pupil after drug-induced mydriasis, caused by the adhesion of
the iris to the lens (Fig. 7). The uveitis model was successfully
achieved in the same way as obtained in our previous studies.36
DISCUSSION
Intravitreal injections are increasingly used in a multitude of
retinal ophthalmic conditions such as age-related macular
degeneration,37 diabetic macular edema,38 macular holes,39
branch and central retinal vein occlusion,40 and endophthal-
mitis.41 The development of new intravitreal drugs or systems
that modify their release involves wide preclinical develop-
ment42 in which pharmacokinetic studies play a key role.43
The use of small animals, such as Sprague Dawley rats, has
many advantages because of their small size, the availability of
research animal facilities, and multiple disease models suitable
for them.44,45 However, since they have a small vitreous
volume, classic pharmacokinetic studies become difficult, with
in vivo imaging being an ideal technique, as no invasive
modalities are required to obtain experimental results.46,47 To
the best of our knowledge, our work is the first study of
intravitreal pharmacokinetics with PET/CT in rats. Previous
intravitreal pharmacokinetic studies have required larger






k, min1 0.00669 0.00656 0.00805 0.00612
t1/2, min 103.6 105.7 86.11 113.2
AUC3600 , % min 140.15 6 14.93 135.23 6 14.09 123.69 6 21.09 137.03 6 5.72
R2 0.9982 0.9982 0.9952 0.9956
* No statistical differences were observed for AUC3600 (% min) between different injection volumes (a n.s.).
† No statistical differences were observed for AUC3600 (% min) between normal and uveitis eyes (a n.s.).
FIGURE 4. Representation of the systemic distribution of radiotracers
at different times after intravitreal administration. (A) Coronal views
after injection of 18F-FDG. (B) Sagittal views after injection of 18F-NaF.
(C) Coronal views after injection of 18F-Choline.
FIGURE 5. Influence of the injection volume on vitreal release (mean
6 SD, n ¼ 8). Intravitreal pharmacokinetic profile of 18F-FDG (A) and
18F-NaF (B) after intravitreal injection of 2, 4, and 7 lL.
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numbers of animals and more complex techniques to
determine vitreous drug levels at different time points.48–50
In our study serial measurements were obtained at multiple
time points after the intravitreal injection in the same animal.
The advantage of preclinical PET/CT images in this field is very
important because the technique is noninvasive, and it yields
images in 3D and real time.51 PET/CT is also becoming a
relevant procedure for ophthalmic research, as it has been
used for diagnosis of intraocular tumors,52 neurophysiological
studies,53,54 or pharmacokinetic studies with topical ophthal-
mic formulations.23 Although PET is a very sensitive technique,
it presents some limitations related to low spatial resolution. As
an example, the delineation of the vitreous area is troublesome
and challenging owing to the small size of the eyeball, and
therefore our measurements cannot be restricted exclusively to
the vitreous area.
More than 10% of currently used drugs contain fluorine
atoms that can be labeled with 18F. Moreover, the substitution
of oxygen atoms or hydroxyl groups by fluorine is relatively
easy with no critical changes in the properties of the
molecule.55 Fluoride and oxygen have a very similar radius,
whereas that of hydrogen is slightly smaller (van der Waals radii
are 1.47, 1.57, and 1.20 angstroms, respectively); therefore,
changing oxygen or hydrogen for fluoride does not entail
substantial modifications in the molecular structure by steric
impediments. Furthermore, in terms of Taft Es parameters,
56
fluoride and hydroxyl substituents have very similar character-
istics (þ0.78 vs. þ0.69); therefore, their substitution does not
compromise either the structural activity of the compound or
its interaction with receptors. The electronegativity of fluoride
and hydrogen atoms is different (4.0 vs. 2.1), hence
interchanging them can substantially affect the physicochem-
ical properties of the molecule (pKa, hydrogen bond capacity,
or lipophilicity). On the contrary, fluoride and oxygen have
similar values (4.0 vs. 3.5), so no major changes should be
expected when interchanged.55 Owing to the relatively short
half-life of 18F, the fluorinated radiotracers have limited use in
studies of pharmacokinetics or biodistribution of drugs with
long half-lives in the vitreous cavity. For these long-term
studies, using other radiotracers with long half-lifes such as 124I
(Kuntner et al.57 and Dangl et al.58) or 89Zr (Van Loon et al.59)
is more adequate.
Fluorinated radiotracers, as the ones used in this work, have
the advantage of their low positron emission energy (the
lowest of all the radiolabels used in PET). Furthermore, the
greater sensitivity of modern PET technology allows the use of
low radioactivity levels, so the dose received and absorbed by
the animal is significantly below the dose limit.60 Additionally,
during the disintegration of 18F, no c rays or a and b particles
are emitted, reducing the dose received by animals and
increasing safety.61 On the other hand, cytotoxicity and acute
irritation of fluorinated radiotracers have been described as
safe in previous reports.23 In our study, no alterations in the
eye of the animals were observed after the administration of
the fluorinated radiotracers.
Our findings showed significant differences between the
different radiolabeled molecules we used. The reason for these
differences could rest on the mechanism used for crossing the
BRB. In the rat retina there are transporters for glucose and
cationic amino acids, which probably are used by 18F-FDG and
18F-Choline to leave the vitreous cavity.62 The biexponential
kinetics we observed is also common for intravitreal drugs
such as bevacizumab and ranibizumab.50,63 Furthermore, it
must be mentioned that hyaluronic acid, which is part of the
vitreous humor, has a highly negative charge at physiological
pH levels. Because of this, it could interact with positively
charged molecules, such as choline, by generating polyelec-
trolyte complexes with low solubility.64 This is probably the
reason why choline is released at a slower rate than glucose.
On the other hand, our findings showed that 18F-NaF is
eliminated from the vitreous, following monoexponential
kinetics, which could be explained by assuming passive
diffusion through the BRB because this compound diffuses
freely across membranes.65 It would be similar to the release
kinetics of other intravitreal drugs, such as aflibercept.66,67
FIGURE 6. Influence of inflammation on vitreal release (mean 6 SD, n
¼ 8). (A) Intravitreal pharmacokinetic profile of 18F-FDG and 18F-NaF
after a 7-lL intravitreal injection in normal eyes and in eyes with
uveitis. (B) Representation of AUC3600 (% min) for
18F-FDG and 18F-NaF
in these conditions. *Statistical significant differences between normal
and uveitis eyes for a < 0.01.
FIGURE 7. Anterior segment of two eyes 24 hours after pad injection
of LPS, showing signs of uveitis. Left: Fibrinous reaction producing a
pupillary membrane. Right: Irregular pupil after drug-induced mydri-
asis caused by the adhesion of the iris to the lens.
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Our findings showed that the injected volume had no
significant influence on vitreous drug clearance. Different
studies have been carried out in human eyes68 and in murine
models69,70 using a wide range of intravitreal injection
volumes (2–20 lL), but they did not include an evaluation
of their impact on the vitreous drug clearance. On the other
hand, it has been pointed out that an increase of intraocular
pressure could result in an increase of hydraulic flow, derived
from the excess of volume introduced.10 This increase in
intraocular pressure could be the cause of the transitory
collapse we observed with the administration of 7 lL.
However, this process seems not to have an effect on the
vitreous clearance of low-molecular-weight drugs,71,72 such
as the ones we used, where all radiolabeled molecules had
molecular weights below 500 Da. Finally, it has to be
mentioned that the vitreous volume of a rat is smaller than
that of humans (approximately 50 lL in rats versus 4.5 mL in
humans)73 (Vezina M, et al. IOVS 2011;52:ARVO E-Abstract
3219). This difference must be kept in mind if our results are
to be translated to humans.
Our results showed an increase in the intravitreal clearance
of the 18F-FDG radiotracer in eyes with inflammation (uveitis)
when compared to healthy eyes. On the contrary, no
significant differences were observed for 18F-NaF. Studies using
MRI techniques have shown that inflammation in rabbit eyes,
induced by LPS, can increase the permeability of BRB.74,75 On
the other hand, additional studies have demonstrated that in
inflammatory conditions, as in tumors, a high FDG uptake and
a high GLUT-1 expression level is observed.76 Of note, 18F-NaF
is not affected by changes produced by the inflammatory
process probably because it is freely diffusible across
membranes.65 However, the increase in permeability and
GLUT transporter under inflammatory conditions can increase
the clearance of 18F-FDG from the vitreous. Since the
magnitude of the clearance changes we found were small, it
would be necessary to carry out additional studies to properly
establish the influence of inflammation on the BRB permeabil-
ity. It is possible that the severity of the inflammatory process
determines the increase of BRB permeability and hence, the
intravitreal clearance rate.
Finally, although the effect of inhaled anesthesia, in
particular isoflurane, on drug permeability has been exten-
sively studied in the blood–brain barrier (BBB), no studies have
shown any type of modification in the status of the BRB.77
Inhaled isoflurane in rats decreases the transfer of small
hydrophilic molecules across the BBB, either by reducing the
perfused capillary surface area or by a direct effect of
isoflurane on the permeability of the BBB.78
Even though BRB and BBB are thought to have similar
properties owing to their similar anatomic features, some
differences in the capillary endothelia at BBB and BRB have
been found.79 These differences could cause a variation in the
permeability across BRB compared to BBB,80 which would
ultimately affect the half-life and clearance of drugs injected
into the vitreous. Therefore, we cannot assume that the
observed increase in permeability through BBB would lead to a
similar effect in BRB. Studies about the effect on inhaled
anesthesia on BRB permeability would be of great interest.
CONCLUSIONS
In summary, we demonstrated for the first time the usefulness
of a PET-based methodology for the study of different factors
influencing intravitreal pharmacokinetics in rats. This can be a
powerful tool to develop new drugs aimed at treating ocular
conditions, using intravitreal administration.
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3. Fernández-Ferreiro A, González-Barcia M, Otero Espinar FJ,
Blanco Méndez J, Lamas MJ. Ophthalmic formulations new
goals [in Spanish]. Farm Hosp. 2016;40:1–2.
4. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug
delivery. AAPS J. 2010;12:348–360.
5. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins
BS. Anti-vascular endothelial growth factor for neovascular
age-related macular degeneration. Cochrane Database Syst
Rev. 2014;8:CD005139.
6. Balachandran RK, Barocas VH. Computer modeling of drug
delivery to the posterior eye: effect of active transport and
loss to choroidal blood flow. Pharm Res. 2008;25:2685–2696.
7. Awwad S, Lockwood A, Brocchini S, Khaw PT. The PK-Eye: a
novel in vitro ocular flow model for use in preclinical drug
development. J Pharm Sci. 2015;104:3330–3342.
8. Park J, Bungay PM, Lutz RJ, et al. Evaluation of coupled
convective–diffusive transport of drugs administered by
intravitreal injection and controlled release implant. J Control
Release. 2005;105:279–295.
9. Krishnamoorthy MK, Park J, Augsburger JJ, Banerjee RK.
Effect of retinal permeability, diffusivity, and aqueous humor
hydrodynamics on pharmacokinetics of drugs in the eye. J
Ocul Pharmacol Ther. 2008;24:255–267.
10. Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and
diffusion in vitreous humor: implications for drug delivery.
Pharm Res. 2000;17:664–669.
11. Gisladottir S, Loftsson T, Stefansson E. Diffusion characteris-
tics of vitreous humour and saline solution follow the Stokes
Einstein equation. Graefes Arch Clin Exp Ophthalmol. 2009;
247:1677–1684.
12. Ohtori A, Tojo K. In vivo/in vitro correlation of intravitreal
delivery of drugs with the help of computer simulation. Biol
Pharm Bull. 1994;17:283–290.
13. Tojo K, Nakagawa K, Morita Y, Ohtori A. A pharmacokinetic
model of intravitreal delivery of ganciclovir. Eur J Pharm
Biopharm. 1999;47:99–104.
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